Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T)

References

• Kim GW, Lee NR, Pi RH, Lim YS, Lee YM, Lee JM, et al. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res. 2015;38(5):575–84.
   PubMed Web of Science ®Google Scholar
• Vasanthi P, Nalini G, Rajasekhar G. Role of tumor necrosis factor-alpha in rheumatoid arthritis: a review. Int J Rheum Dis. 2007;10(4):270–4.
   Google Scholar
• Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14(1):397–440.
   PubMed Web of Science ®Google Scholar
• Detert J, Klaus P. Biologic monotherapy in the treatment of rheumatoid arthritis. Biol Targets Ther. 2015;9:35–43.
   PubMedGoogle Scholar
• Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis. 2011;2011:765624.
   PubMedGoogle Scholar
• Srirangan S, Choy EH. The role of interleukin-6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2(5):247–56.
   PubMedGoogle Scholar
• Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830–5.
   PubMed Web of Science ®Google Scholar
• Strand V, Burmester GR, Ogale S, Devenport J, John A, Emery P. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology. 2012;51(10):1860–9.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73(9):1616–25.
   PubMed Web of Science ®Google Scholar
• Hennigan S, Kavanaugh A. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2008;4(4):767–75.
   PubMedGoogle Scholar
• Jordan N, Lutalo PM, D’Cruz DP. Novel therapeutic agents in clinical development for systemic lupus erythematosus. BMC Med. 2013;11(1):120.
   PubMedGoogle Scholar
• Ogata A, Hirano T, Hishitani Y, Tanaka T. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2012;5:27–42.
   PubMedGoogle Scholar
• Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol. 2011;72(2):270–81.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Pang J, Shuster D, Hung C, Baglino S, Dodge R, et al. Anti-IL-6 antibody clazakizumabiIs more potent than tocilizumab in blocking in vitro and ex vivo IL-6-induced functions. Arthritis Rheum. 2013;65(Suppl):S1020.
   Google Scholar
• Aletaha D, Bingham CO, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet. 2017;389(10075):1206–17.
   PubMed Web of Science ®Google Scholar
• Fleischman R, van Adelsberg J, Lin Y, Castelar-Pinheiro G, Brzezicki J, Hrycaj P, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheum. 2017;69(2):277–290.
   Web of Science ®Google Scholar
• Emery P, Keystone E, Tony H, Cantagrel A, Van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24–week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–23.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;363(14):1303–12.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–806.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Thorne C, Karpouzas G, Sheng S, Xu W, Rao R, et al. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Ann Rheum Dis. 2017;76(12):2001–8.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Yamanaka H, Harigai M, Tamamura R, Kato Y, Ukyo Y, et al. One-year safety of sirukumab monotherapy: results from a randomized, double-blind, parallel-group, multicenter study in Japanese subjects with moderate to severe rheumatoid arthritis. Arthritis Rheumatol. 2015;67(Suppl 10):2063–5. Abstract 1672.
   Web of Science ®Google Scholar
• Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73(9):1626–34.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014;73(9):1607–15.
   PubMed Web of Science ®Google Scholar
• Michaud K, Berglind N, Franzén S, Frisell T, Garwood C, Greenberg JD, et al. Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Ann Rheum Dis. 2016;75:1797–805.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Goto H, Hirao K, Nakajima A, Origasa H, Tanaka K, et al. Long term safety of tocilizumab: results from 3 years of follow up postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol. 2015;42:1368–75.
   PubMed Web of Science ®Google Scholar